Medincell SA

A new report from DelveInsight reveals that more than 28 companies are actively developing over 30 pipeline drugs for tuberculosis. Key players include Biofabri, Otsuka Pharmaceutical, GlaxoSmithKline, Archivel Farma, BioNTech, CanSino Biologics Inc., Medincell, and others, with promising therapies such as MTBVAC, Quabodepistat, GSK3036656, RUTI, BNT164, and Ad5-105K in various clinical stages. Approximately four-plus drugs are in late-stage development, and notable mechanisms of action include leucyl-tRNA synthetase inhibitors, immunostimulants, and DprE1 protein inhibitors. The report also highlights recent milestones, including the first patient dosed in a Phase IIb trial of alpibectir-ethionamide in March 2026 and the initiation of a new cohort in the IMAGINE trial of MTBVAC in February 2026.

Medincell SA reported full year 2026 earnings, highlighting progress in its Shift to Growth strategy and a rise in royalties from UZD, while total income dipped to $24.3 million from $27.7 million a year earlier due to the absence of milestone payments. Net sales of UZD by Teva reached $215 million, up from $141 million, and Olanzapine LAI is on track for a U.S. launch in the fourth quarter of 2026 with FDA submissions accepted. Operating expenses increased to EUR 45 million from EUR 38.5 million, resulting in an operating loss of EUR 20.8 million, though the company maintains a strong cash position of EUR 85 million. CEO Christophe Duarte noted Teva's conservative guidance and expects Olanzapine LAI to launch immediately upon approval, while CFO Stefan Postic addressed foreign exchange exposure by aligning expenses with USD revenues where possible. The company is expanding its pipeline with 15 active programs and confirmed that AbbVie's first candidate will start clinical development in 2027.